Moleculaire integratie en gerichte therapieën bieden nieuwe perspectieven bij monomorf epitheeliotroop intestinaal T-cel-lymfoom

Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare and highly aggressive type of intestinal T-cell lymphoma. With the application of high-throughput sequencing technologies in recent years, the understanding of this entity has become increasingly comprehensive. The World Health Organization classification of lymphoma now recognizes MEITL as a distinct disease entity. However, the extreme rarity of MEITL poses substantial challenges for clinical diagnosis and management, and patient outcomes remain poor. Based on a systematic review of recent literature, this article summarizes the diagnostic criteria of MEITL, integrating pathology and molecular biology; outlines current multimodal treatment approaches centered on surgery, chemotherapy, and hematopoietic stem cell transplantation; and reviews available clinical and translational data to explore the potential role of epigenetic agents, JAK/STAT pathway inhibitors, and other emerging therapeutic strategies in MEITL. This article summarizes the current status and recent advances in the diagnostic and therapeutic strategies for MEITL in clinical practice and provides a reference for the design of future prospective, multicenter clinical studies.